Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-grass pollen extract is a sublingual immunotherapy (SLIT) used for treating grass pollen-induced allergic rhinoconjunctivitis, with or without mild asthma. The specific formulation mentioned in clinical studies contains standardized extracts from three grass pollens: Dactylis glomerata (Orchard grass), Lolium perenne (Perennial ryegrass), and Poa pratensis (Kentucky bluegrass). Administered as sublingual drops, the treatment aims to desensitize the immune system to these common allergens. This immunomodulatory process is thought to work by shifting the immune response from a Th2-mediated allergic reaction to a more tolerant Th1/Treg-mediated response. This is evidenced by an increase in allergen-specific IgG4 antibodies, which act as "blocking antibodies," leading to a reduction in allergy symptoms upon natural exposure to grass pollen. The product is developed and manufactured by Stallergenes Greer under the brand name Staloral.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-grass pollen extract.